Trials / Completed
CompletedNCT05110846
A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple-Center Study to Evaluate the Efficacy, Safety, and Tolerability of CT-868 Administered for 26 Weeks to Overweight and Obese Participants With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 103 (actual)
- Sponsor
- Carmot Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A study to assess the effect of CT-868 in lowering glycated hemoglobin A1c (HbA1c) in overweight and obese participants with inadequately controlled Type 2 diabetes mellitus (T2DM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Participants self-injected once-daily subcutaneous volume- and regimen-matched placebo for 26 weeks. |
| DRUG | CT-868 | Participants self-injected once-daily subcutaneous CT-868 for 26 weeks according to the randomized dose and regimen. |
Timeline
- Start date
- 2022-02-22
- Primary completion
- 2023-02-28
- Completion
- 2023-02-28
- First posted
- 2021-11-08
- Last updated
- 2026-02-05
Locations
5 sites across 1 country: Mexico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05110846. Inclusion in this directory is not an endorsement.